TOKYO--(BUSINESS WIRE)--DIC Corporation (TOKYO:4631) announced today that it will participate in CES 2026, one of the world’s leading technology trade shows for the consumer electronics industry, ...
A fourth ex-US Coast Guard cutter has been transferred to the Sri Lanka Navy, US Ambassador to Sri Lanka, Julie Chung, said yesterday. Posting on X, Chung said the vessel will embolden Sri Lanka’s ...
There are two built-in ways to view, customize, and clear your Personal Dictionary on a Windows 11 computer. These are: Using the Settings app Using the default.dic file. Let’s check both ways one by ...
The syndrome of disseminated intravascular coagulation (DIC) is a serious hypercoagulation state that occurs in a variety of disease states, including cancer. Although DIC is often associated with ...
DIC can be acute or chronic in nature. Chronic DIC is generally seen in the cancer population and is demonstrated as localized thrombotic events (eg, deep vein thromboses). Chronic DIC is defined as a ...
The latest price target for Silence Therapeutics (NASDAQ:SLN) was reported by HC Wainwright & Co. on September 16, 2025. The analyst firm set a price target for $75.00 expecting SLN to rise to within ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed, investigational system that aims to fracture hardened calcium within the ...
Abbott Laboratories emphatically let Boston Scientific and Johnson & Johnson know it wanted a piece of the intravascular lithotripsy (IVL) space. The Abbott Park, IL-based company reported FDA had ...
Sentinel lymph node (SLN) biopsy for early cervical cancer achieved non-inferiority versus pelvic lymphadenectomy, according to results of a large randomized study from China. Patients assigned to SLN ...
Goldman Sachs initiated Silence Therapeutics (NASDAQ:SLN) with a Sell rating and a $6 price target on Tuesday, arguing that with only about $173M of cash and equivalents at the end of Q3 2024, the U.K ...
Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt () (NasdaqGM:SLN) with a Sell recommendation. As of March 27, 2023, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback